LSV Asset Management Trims Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

LSV Asset Management reduced its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 42.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,300 shares of the company's stock after selling 12,600 shares during the quarter. LSV Asset Management's holdings in Pacira BioSciences were worth $326,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of PCRX. Caitlin John LLC lifted its holdings in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after acquiring an additional 1,776 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after buying an additional 513 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after buying an additional 918 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Pacira BioSciences in the fourth quarter worth about $190,000. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Performance

Shares of PCRX traded up $1.51 during trading hours on Monday, hitting $26.16. The stock had a trading volume of 261,881 shares, compared to its average volume of 971,572. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The stock has a fifty day moving average price of $24.55 and a 200 day moving average price of $21.19. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The firm has a market capitalization of $1.21 billion, a PE ratio of -12.93 and a beta of 0.71.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PCRX shares. HC Wainwright upped their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Barclays upped their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $26.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.